BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OrcaGraft (Orca-Q) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of OrcaGraft (Orca-Q)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05322850-2880@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:OrcaGraft (Orca-Q): Phase 1/2 readout est. (NCT05322850)
DESCRIPTION:OrcaGraft (Orca-Q)\, phase 1/2\, Acute Myeloid Leukemia.\nStudy
 : Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopo
 ietic Cell Transplant (HCT)\nEstimated primary completion: September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/orcagraft-orca-q#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0532285
 0
URL:https://assetmemo.bio/drug/orcagraft-orca-q#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03802695-2880@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:OrcaGraft (Orca-Q): Phase 1 readout est. (NCT03802695)
DESCRIPTION:OrcaGraft (Orca-Q)\, phase 1\, Acute Myeloid Leukemia.\nStudy: 
 A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantat
 ion for Hematologic Malignancies\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/orcagraft-orca-q
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT038
 02695
URL:https://assetmemo.bio/drug/orcagraft-orca-q#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06900192-2880@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:OrcaGraft (Orca-Q): Phase 1 readout est. (NCT06900192)
DESCRIPTION:OrcaGraft (Orca-Q)\, phase 1.\nStudy: A Multicenter Phase 1 Stu
 dy of Orca-Q in Primary Progressive Multiple Sclerosis\nEstimated primary 
 completion: June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/orcagraft-orca-q#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06900192
URL:https://assetmemo.bio/drug/orcagraft-orca-q#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759102-2880@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20320901
DTEND;VALUE=DATE:20320902
SUMMARY:OrcaGraft (Orca-Q): Phase 1 readout est. (NCT07759102)
DESCRIPTION:OrcaGraft (Orca-Q)\, phase 1.\nStudy: Allogeneic ORCA-Q Stem Ce
 ll Transplant for the Treatment of Relapsed and Refractory High Risk Multi
 ple Myeloma\nEstimated primary completion: 1 September 2032. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/orcagraft-orca-q#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07759102
URL:https://assetmemo.bio/drug/orcagraft-orca-q#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
